Colonic effects of TAK-637:: A novel NK1 receptor antagonist.

被引：0
|
作者：
Venkova, K
Tyler, K
Sutkowski-Markmann, D
Greenwood-Van meerveld, B
机构：
[1] Oklahoma Fdn Digest Res, Basic Sci Lab, Oklahoma City, OK USA
[2] TAP Pharm Prod Inc, Deerfield, IL USA
来源：
GASTROENTEROLOGY | 2001年 / 120卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1707
引用
收藏
页码：A331 / A331
页数：1
相关论文
共 50 条
  • [21] EFFECTS OF INTRATHECAL FK888, A NOVEL DIPEPTIDE NK1 RECEPTOR ANTAGONIST, ON THE FORMALIN TEST IN THE RAT
    YAMAMOTO, T
    SHIMOYAMA, N
    MIZUGUCHI, T
    NEUROSCIENCE LETTERS, 1993, 161 (01) : 57 - 59
  • [22] Opioid activity of sendide, a tachykinin NK1 receptor antagonist
    Sakurada, T
    Yuhki, M
    Inoue, M
    Sakurada, C
    Koichi, TN
    Ohba, M
    Kisara, K
    Sakurada, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 369 (03) : 261 - 266
  • [23] MEN 11149, a potent antagonist of the tachykinin NK1 receptor
    Astolfi, M
    Parlani, M
    Lopez, G
    Conte, B
    Cirillo, R
    Fincham, CI
    Terracciano, R
    Manzini, S
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 : P202 - P202
  • [24] The NK1 receptor antagonist serlopitant for treatment of chronic pruritus
    Staender, Sonja
    Spellman, Mary C.
    Kwon, Paul
    Yosipovitch, Gil
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (08) : 659 - 666
  • [25] Spinal neurokinin NK1 receptor down-regulation and antinociception: Effects of spinal NK1 receptor antisense oligonucleotides and NK1 receptor occupancy
    Hua, XY
    Chen, P
    Polgar, E
    Nagy, I
    Marsala, M
    Phillips, E
    Wollaston, L
    Urban, L
    Yaksh, TL
    Webb, M
    JOURNAL OF NEUROCHEMISTRY, 1998, 70 (02) : 688 - 698
  • [26] Potent nonpeptide antagonist of the substance P (NK1) receptor
    Snider, R.M.
    Constantine, J.W.
    Lowe, J.A. III
    Longo, K.P.
    Lebel, W.S.
    Woody, H.A.
    Drozda, S.E.
    Desai, M.C.
    Vinick, F.J.
    Science, 1991, 251 (4992)
  • [27] Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression
    Mark S Kramer
    Andrew Winokur
    Jeffrey Kelsey
    Sheldon H Preskorn
    Anthony J Rothschild
    Duane Snavely
    Kalyan Ghosh
    William A Ball
    Scott A Reines
    Dennis Munjack
    Jeffrey T Apter
    Lynn Cunningham
    Mitchel Kling
    Mohammed Bari
    Albert Getson
    Yih Lee
    Neuropsychopharmacology, 2004, 29 : 385 - 392
  • [28] Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression
    Kramer, MS
    Winokur, A
    Kelsey, J
    Preskorn, SH
    Rothschild, AJ
    Snavely, D
    Ghosh, K
    Ball, WA
    Reines, SA
    Munjack, D
    Apter, JT
    Cunningham, L
    Kling, M
    Bari, M
    Getson, A
    Lee, Y
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 (02) : 385 - 392
  • [29] In vitro pharmacological characterisation of a novel NK1 receptor antagonist, vestipitant (GW597599)
    Griffante, C
    Carletti, R
    Cavanni, P
    Alvaro, G
    Di Fabio, R
    Donati, D
    Corsi, M
    Trist, DG
    Ratti, E
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S551 - S551
  • [30] Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist
    Walpole, CSJ
    Brown, MCS
    James, IF
    Campbell, EA
    McIntyre, P
    Docherty, R
    Ko, S
    Hedley, L
    Ewan, S
    Buchheit, KH
    Urban, LA
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (01) : 83 - 92
12345